How to Start a Business Like Hims & Hers

Machine one: a brand that sells care like a consumer product

The original insight was packaging: taking conditions people avoid talking about (hair loss, sexual health, later weight) and wrapping clinical care in direct-to-consumer branding, plain language, and e-commerce mechanics. The product is a subscription program, the tone is a lifestyle brand, and the clinical machinery stays backstage where licensed clinicians run it.

This machine is the most replicable part, and the place founder-scale brands hold a real advantage: a creator, community, or niche brand starts with trust Hims has to buy. What transfers is the discipline, not the logo: one clearly named audience, one entry problem that audience actually has, care presented in the audience's own language, and marketing that survives a regulator reading it aloud (the FTC's substantiation and testimonial rules apply at every scale, and so does the no-outcome-promises line).

Machine two: the cash-pay clinical engine

Underneath the brand is the structure this site documents everywhere: cash-pay pricing that skips insurance operations entirely, telehealth visits (largely asynchronous where states permit) with licensed clinicians making every prescribing decision independently, and the corporate-practice separation between the business and the medical groups. Cash-pay is what makes the economics product-like: transparent prices, subscription billing, no payer enrollment.

For a founder, this machine used to be the build: clinical entities, multi-state clinician coverage, protocols, compliance. It is now the most commoditized layer of the model, in the good sense: operated white-label platforms and clinical networks supply the same structural engine behind your brand, which is precisely the unbundling that makes like-Hims businesses launchable without Hims capital. The structure rules still bind at every scale; our triangle and MSO guides cover what can never be shortcut.

Machine three: supply economics, the quiet one

The public record shows how seriously the model takes the supply side. In the GLP-1 era, Hims & Hers moved through the whole arc: compounded semaglutide offerings during the shortage years, a partnership with Novo Nordisk announced in April 2025 bundling branded Wegovy into its platform at $599 a month all-in, that partnership's public collapse weeks later, and, per legal-industry reporting on the March 2026 settlement with Novo, an end to compounded semaglutide for new patients. Meanwhile the manufacturers built their own cash channels and pushed the public price floor down hard.

The founder lesson is not any one of those moves; it is that medication economics are the P&L in recurring-Rx categories, and whoever owns the supply relationship owns the margin. At founder scale you will not own pharmacies, which makes the supply question your single most important platform-diligence item: who dispenses, what a fill costs, who keeps the spread, and what happens when a product's status moves. Every supply mistake in this category's public record is a version of skipping that diligence.

The supply arc in one sourced line: the category went from compounded-era pricing, through a $599/month branded partnership announced and unwound in 2025, to manufacturer cash channels selling Wegovy at $349 by late 2025. Founder translation: never build a pricing story on a supply posture you don't have in writing.

Machine four: subscription discipline measured in years

The model's economics run on tenure. Hims & Hers' own shareholder reporting headlines revenue retention of multi-year-tenure subscriptions as a key metric, and independent credit-card panel data (Earnest Analytics, 2024) showed its average monthly tickets climbing as GLP-1 programs scaled. The company reports those numbers because tenure is where the model lives or dies, which matches the category's published persistence research: a hard early cliff, and durable value in the cohorts that stay.

This machine is fully replicable because it is operational, not capital: honest onboarding, refill continuity that never lapses, price predictability, adjacent care lines so finishing one journey doesn't mean leaving, and dunning that catches the card declines masquerading as churn. Our retention-benchmarks and revenue-per-patient guides carry the sourced numbers and the levers; a founder-scale brand executing them competes on the metric that matters.

Machine five: category expansion, and where founders should differ

Hims expanded horizontally: hair to sexual health to skin to mental health to weight, one brand spanning many categories, fed by mass-market acquisition. That breadth is the part not to copy: it requires acquisition spend and brand elasticity that only scale buys, and chasing it early is how focused brands become unfocused ones with the same budget.

The founder-scale version inverts it: go deep in one audience instead of wide across categories. A fitness community's brand can ladder weight, hormones, and recovery care for the same members; a women's-health creator can serve one audience's whole adjacent menu. Expansion then means switching on the next care line for people who already trust you, which the platform model makes a configuration change rather than a build.

• Copy: the brand discipline, the cash-pay engine, the subscription machinery, the supply diligence
• Don't copy: nine-figure media spend, horizontal category sprawl, supply postures you can't document
• Your structural advantage: an audience that already trusts you, which Hims pays to manufacture
• Your structural constraint: the triangle binds at every scale; there is no growth-hack exemption

The founder-scale build, concretely

The sequence is the one our launch guides detail: pick the audience and entry care line, stand the five components up on operated rails or assemble them with counsel, start the certification clock on day one if paid acquisition is in the plan, launch to owned audience while it runs, and build the retention machinery before the growth spend. The economics get modeled the honest way (contribution per patient per month times tenure checkpoints), against the public price floor your patients can see.

EmbedCare is the operated version of machines two and three with machine four built in: 50-state clinicians making every prescribing decision, owned pharmacy supply with medication included in flat product rates on GLP-1 programs, the storefront to certification standards, and the retention machinery running from day one, behind your brand. The Launch tier starts at $495/mo, and the demo conversation is exactly this guide with your audience in it.